Publication: Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study
6
Issued Date
2021-01-01
Resource Type
ISSN
15210669
08880018
08880018
Other identifier(s)
2-s2.0-85106128757
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pediatric Hematology and Oncology. Vol.38, No.4 (2021), 346-357
Suggested Citation
Thaksin Jansing, Kleebsabai Sanpakit, Trai Tharnpanich, Thanjira Jiranantakan, Vachira Niphandwongkorn, Busba Chindavijak, Thanarat Suansanae Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study. Pediatric Hematology and Oncology. Vol.38, No.4 (2021), 346-357. doi:10.1080/08880018.2020.1871136 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78738
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study
Other Contributor(s)
Abstract
Busulfan (Bu) is commonly used in myeloablative conditioning regimens for children undergoing hematopoietic stem cell transplantation. The standard target area under the concentration-time curve (AUC) of Bu is approximately 900–1500 µM min. In previous studies using five fixed doses (0.8–1.2 mg/kg) for Bu without dose adjustment, 75% patients achieved the target AUC. The aim of this pilot study was to determine the percentage of target AUC for intravenous (IV) Bu in Thai children. IV Bu was administered every 6 h over 16 doses. Blood samples were collected for pharmacokinetic (PK) analysis after the first, ninth, and thirteenth doses of Bu. Seven patients (2–14 years; median 6 years) were diagnosed with thalassemia (n = 4), acute myeloid leukemia (n = 2), and pure red cell aplasia. Three, two, and two patients received Bu at 1.1, 1.2, and 0.8 mg/kg, respectively. The AUC of Bu varied from 292–1714 µM min (median = 804). Nine (42.86%), eleven (52.38%), and one (4.76%) AUC values were within, below, and above the target, respectively. The median (range) Bu clearance was 5.93 (1.91–14.65) mL/min/kg. In this study, 42.86% AUC value achieved the target, which was lower than that in previous studies. Therapeutic drug monitoring (TDM) of Bu should be considered in Thai children receiving five fixed doses of IV Bu, and dose adjustment should be performed as necessary. Further PK studies for Bu with a larger sample size are warranted for confirming the necessity of TDM in every step dose of Bu. (Trial registration numbers; TCTR20190528003).